0802 GMT - AstraZeneca should have a catalyst-rich year with seven late-stage trial results, Berenberg analysts say in a note. However, the company faces headwinds from a lower-performing China business and generics of its type-2 diabetes drug Farxiga, Berenberg says. The British pharma major expects a China sales decline in 4Q and 2025. This is due to its continuing anticorruption investigation of its China employees, but AstraZeneca has strong underlying momentum in the rest of its business, the analysts say. Berenberg forecasts 2025 sales growth of 10%, at constant currencies, and EPS growth of 14%, both lower than the company's guided high teens growth rate for 2024. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 20, 2025 03:02 ET (08:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。